Explore more price target data and ratings for Repligen Corporation on the Forecasts tab, and track all previous and future analyst recommendations for Repligen Corporation in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This info…
What Happened? Shares of biopharma manufacturing company Repligen Corporation NASDAQ:RGENjumped 14.6% in the afternoon session after the company reported second-quarter results that beat analyst expectations and raised its full-year forecast.The company posted adjusted earnings of $0.54 per share…
Q2 2026 saw 13% organic revenue growth, margin expansion, and strong performance in proteins and analytics. Full-year guidance was raised for revenue and EPS, with BioLife acquisition set to accelerate cell therapy growth and deliver financial synergies.Based on Repligen Corporation [RGEN] Q2 2026…
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance p…
The $1.5 billion acquisition of BioLife Solutions accelerates leadership in cell therapy, adds a highly complementary portfolio, and is expected to be accretive to growth, margins, and EPS from year one. Integration is planned over 12–24 months, with at least $20 million in year one synergies and s…
The $1.5B acquisition of BioLife Solutions accelerates leadership in cell therapy, adds a highly complementary portfolio, and is immediately accretive to growth and margins. Integration is expected to be straightforward, with significant cost and revenue synergies, especially in Asia-Pacific.Based…
A $1.5 billion acquisition will expand cell therapy capabilities and recurring revenue, with BioLife stockholders receiving a 24% premium. The deal is expected to be accretive, deliver significant synergies, and close in Q4 2026, pending regulatory and stockholder approvals.Original document: Repli…
The acquisition creates a leading cell therapy solutions provider, combining differentiated platforms and expanding offerings in a high-growth market. The $1.5B deal is accretive to growth, margins, and EPS, with clear synergies and a straightforward integration plan.Original document: Repligen Cor…
What Happened? Shares of biopharma manufacturing company Repligen Corporation NASDAQ:RGENfell 7% in the morning session after investors reacted to the company's weak full-year guidance ahead of its upcoming earnings report, alongside concerns over project delays highlighted by industry peer Danaher…
(17:06 GMT) Repligen Price Target Raised to $160.00/Share From $150.00 by Evercore ISI Group
